Investors who suffered losses related to Fractyl Health, Inc. (GUTS) may seek to lead an ongoing securities fraud class action announced by the Law Offices of Frank R. Cruz. The lead plaintiff deadline is October 20, 2026. The complaint alleges that, between January 13, 2025, and January 29, 2026, defendants made materially false or misleading statements and failed to disclose adverse facts about the company’s business, operations and prospects. It claims Revita was less effective than investors had been led to believe and that operational issues at one or more clinical sites in the REMAIN-1 Midpoint Cohort compromised the integrity of efficacy results. The complaint further alleges that Fractyl Health’s clinical, regulatory and commercial prospects, as well as the cohort’s ability to assess Revita’s efficacy, were overstated. Investors do not need to take action to remain absent class members and may retain counsel of their choice or take no action.